Availability and Approval

Retatrutide is not currently available for prescription or purchase. Its pivotal Phase 3 trials are complete, and on July 23, 2026 Eli Lilly said it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Based on that guidance, FDA approval could come as early as late 2027 (with Priority Review) and more likely in the first half of 2028, with commercial availability in 2028.

The main legitimate way to receive retatrutide is participation in an authorized clinical trial. Since August 2026 there is also a narrow expanded access program (NCT07629401) for adults with a BMI of 35 or higher despite maximal approved therapy and two or more serious obesity-related complications, which a treating physician must request from Eli Lilly. The drug is not approved for prescription, and purchasing it outside of a clinical trial setting is not sanctioned by regulatory authorities. We strongly advise against obtaining any investigational compound through unregulated channels.

In all clinical trials to date, retatrutide has been administered as a once-weekly subcutaneous injection. If approved, it is expected to be available initially as an injectable formulation. Whether an oral formulation might be developed in the future is unknown and would require separate clinical development.

Pricing has not been determined, as retatrutide has not been approved for marketing. For context, other incretin-based obesity medications (semaglutide, tirzepatide) carry list prices in the range of approximately $1,000-$1,300 per month in the United States, though net prices after insurance and rebates vary widely. Retatrutide pricing will depend on its approved indications, competitive positioning, insurance coverage decisions, and Eli Lilly's pricing strategy.

Insurance coverage decisions cannot be predicted at this time. Coverage for obesity medications has historically been limited, though it has been expanding in recent years as the medical community increasingly recognizes obesity as a chronic disease requiring pharmacological treatment. Coverage will depend on the approved indications, individual insurance plans, and payer policies at the time of potential approval.

If retatrutide receives FDA approval, Eli Lilly would be expected to pursue regulatory submissions in other major markets, including the European Union (through the EMA), Japan, Canada, Australia, and other countries. International approval timelines typically lag behind U.S. approval by 6-18 months, depending on the regulatory agency and submission timing.